TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates-Reference-Cited by-同舟云学术

TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates

Published:2003-11 Issue:2 Volume:14 Page:205-217
ISSN:0969-9961
Container-title:Neurobiology of Disease
language:en
Short-container-title:Neurobiology of Disease

Author:

Andringa Gerda,Eshuis Silvia,Perentes Elias,Maguire R.Paul,Roth Daniel,Ibrahim Merdol,Leenders Klaus L,Cools Alexander R

Publisher

Elsevier BV

Subject

Neurology

Reference54 articles.

1. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells;Abu-Raya;Eur. J. Pharmacol.,2002

2. The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey;Andringa;J. Neural Transm.,2000

3. The predictive validity of the drug-naive bilaterally MPTP-treated monkey as a model of Parkinson's disease;Andringa;Behav. Pharmacol.,1999

4. Systemic administration of the propargylamine CGP 3466B prevents behavioural and morphological deficits in rats with 6-hydroxydopamine-induced lesions in the substantia nigra;Andringa;Eur. J. Neurosci.,2000

5. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease;Anglade;Histol. Histopathol.,1997

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Trials and Outcomes in Anti-inflammatory Therapies;Inflammation Resolution and Chronic Diseases;2024

2. Parkinson’s Disease: A Comprehensive Overview of the Disease;Parkinson’s Disease - Animal Models, Current Therapies and Clinical Trials;2023-12-20

3. Current Therapies in Clinical Trials of Parkinson’s Disease: A 2021 Update;Pharmaceuticals;2021-07-25

4. PCMT1 Ameliorates Neuronal Apoptosis by Inhibiting the Activation of MST1 after Subarachnoid Hemorrhage in Rats;Translational Stroke Research;2017-05-22

5. Therapeutic Strategies in Neurodegenerative Diseases;Neuroimmune Pharmacology;2016-12-23